USPTO serial 98220959
AQUEDUCT
Reviewed by CopyMark Law Group
Status 605
- Filing date
- Status date
- Registration date
- —
- Examiner
- SCHRADER, BRITTANY A
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with AQUEDUCT?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
THOMAS Y. YEE
THOMAS Y. YEE PERKINS COIE LLPP.O. BOX 2608SEATTLE, WA 98111UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 035 | Business consulting and data management in the field of clinical trials, namely, providing information management services by means of data compilation; collection, reporting, managing, structuring, activating, and analysis of healthcare records, clinical records, and life science report and article-related data for business purposes; services consisting of the registration, collection, transcription, compilation, clarification, enablement, enhancement, management, mapping, structuring, activating, and systemization of written communications and data; all of the foregoing services provided to healthcare providers and researchers for medical diagnosis and treatment purposes and not for medical and health care education and may also be provided by means of artificial intelligence | ABANDONED | — |
| 038 | Providing access to an electronic exchange of health data and data analyses across an integrated nationwide clinical research network; transmission of health and medical record and life science report and article database information and analyses of health and medical record and life science report and articles database information via telecommunications networks; electronic exchange of health data and life science report and articles insights via telecommunication networks for analyses, managing, structuring, activating, of health data from clinicians, health systems, academic medical centers, life sciences companies, and others; electronic transmission of health data; all of the foregoing services provided to healthcare providers and researchers for medical diagnosis and treatment purposes and not for medical and health care education and may also be provided by means of artificial intelligence | ABANDONED | — |
| 042 | Providing medical, health, and scientific research information, research data, and research services to assist healthcare providers, healthcare professionals, and life sciences companies in making informed decisions for patient diagnosis and treatment and clinical trial design, emulation, strategy, and prioritization; medical research services, namely, collecting, storing, indexing, analyzing, updating, managing, sharing, and reporting real world data to create actionable insights for use by healthcare providers, healthcare professionals, and life sciences companies; providing medical and scientific research information in the field of clinical trials and life sciences; compiling data for research purposes in the field of medical science and medical consultancy and life sciences; software as a service (SAAS) services featuring software for providing diagnosis and treatments recommendations for physicians and researchers; software as a service (SAAS) services featuring software for collecting, storing, indexing, analyzing, updating, managing, sharing, clarifying, enabling, enhancing, managing, mapping, structuring, activating, and reporting clinical trial, data, electronic health records, claims data, life science articles and report, and medical research data to evaluate and recommend medical diagnoses and treatments; software as a service (SAAS) services featuring software for searching, organizing and managing data, namely, demographics, diagnoses, procedures, medications, laboratory values, clinical notes, mortality, and length of stay information for patients to inform clinical care decisions and research; software as a service (SAAS) services featuring software for providing healthcare providers and healthcare professionals with custom tailored information about the range of possible diagnoses and therapies associated with a defined set of symptoms; software as a service (SAAS) services featuring software for compiling, clarifying, enabling, enhancing, managing, mapping, structuring, activating, and analyzing medical records and health data and life science articles and reports; software as a service (SAAS) services featuring software using a natural language or large language model, artificial intelligence, and machine learning for compiling, clarifying, enabling, enhancing, managing, mapping, structuring, activating, and analyzing medical records and health data and life science articles and reports; software as a service (SAAS) services featuring chatbot software using a natural language or large language model or artificial intelligence for compiling, clarifying, enabling, enhancing, managing, mapping, and analyzing medical records and health data and life science articles and reports and providing tailored reports regarding the data to physicians and researchers; compiling data for research purposes in the field of medical science and medical consultancy; software as a service (SAAS) services featuring software for data management, structuring and activation; all of the foregoing services provided to healthcare providers and researchers for medical diagnosis and treatment purposes and not for medical and health care education | ABANDONED | — |
| 044 | Providing medical information to healthcare providers and healthcare professionals, and life sciences companies to help them make informed decisions for patient diagnosis and treatment and clinical trial design, emulation, strategy, and prioritization; providing health data analysis to healthcare providers and healthcare professionals in the medical and patient-care industry to help them to assess clinical data for the purpose of patient diagnosis and treatment and improving quality of care in the medical and healthcare industry; providing information and data related to patient data, namely, demographics, diagnoses, procedures, medications, laboratory values, clinical notes, mortality, and length of stay information for patients to inform clinical care decisions and research and to inform life science company corporate strategy, research and development, and marketing and brand planning; providing on-line medical and clinical record and life science articles and reports analysis services designed to provide healthcare providers and healthcare professionals with custom tailored information about the range of possible diagnoses and therapies associated with a defined set of symptoms; providing on-line medical and clinical record and life science articles and reports analysis services designed to provide medical providers with custom tailored information about the outcomes for patients with similar symptoms and evidence needed for patient care decisions; compiling, clarifying, enabling, enhancing, managing, mapping, and analyzing medical and clinical data and life science articles and reports for medical treatment purposes; all of the foregoing services provided to healthcare providers and researchers for medical diagnosis and treatment purposes and not for medical and health care education and may also be provided by means of artificial intelligence | ABANDONED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Atropos Health, Inc.
- Other trademarks owned by Atropos Health, Inc.
- Other trademarks in Class 035
- Other trademarks in Class 038
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named AQUEDUCT
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 10, 2026 | ETOP | EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED | — |
| Apr 16, 2026 | MAB5 | ABANDONMENT NOTICE E-MAILED - AFTER PUBLICATION | — |
| Apr 16, 2026 | ABN5 | ABANDONMENT - AFTER PUBLICATION | — |
| Apr 15, 2026 | EXAR | TEAS EXPRESS ABANDONMENT RECEIVED | — |
| Mar 11, 2026 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| Feb 10, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Feb 10, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 4, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jan 16, 2026 | EXPT | EXPARTE APPEAL TERMINATED | — |
| Jan 16, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 16, 2026 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jan 16, 2026 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jan 16, 2026 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jan 16, 2026 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jul 12, 2025 | EXPI | EX PARTE APPEAL-INSTITUTED | — |
| Jul 12, 2025 | JURT | JURISDICTION RESTORED TO EXAMINING ATTORNEY | — |
| Jul 12, 2025 | EXAF | EXPARTE APPEAL RECEIVED AT TTAB | — |
| Jul 11, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 11, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 11, 2025 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Apr 9, 2025 | XELG | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | — |
| Apr 9, 2025 | XELR | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | — |
| Jan 13, 2025 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Jan 13, 2025 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jan 13, 2025 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jun 25, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 25, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 25, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 11, 2024 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 11, 2024 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 11, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 30, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 16, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 16, 2023 | NWAP | NEW APPLICATION ENTERED | — |